Zimmer Biomet declares $0.24 quarterly dividend By Investing.com
Zimmer Biomet Holdings, Inc. announced a quarterly cash dividend of $0.24 per share for Q2 2026, payable on July 31, 2026. This follows strong financial results for Q1 2026, where the company exceeded earnings and revenue forecasts, though analysts have adjusted price targets due to perceived risks. The company also increased its 2026 share repurchase plan to $1 billion.
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports
Lantheus Holdings is reportedly considering a sale following a $7 billion takeover offer from private-equity-backed Curium Pharma. The two radiopharmaceutical companies have been in discussions, with a potential deal possibly weeks away, though no final decision has been made. Lantheus's shares were down nearly 2% in extended trading but have gained significantly this year.
Jazz Pharmaceuticals plc SEC Filing
Jazz Pharmaceuticals plc has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details the sale of 2,741 shares of common stock with an aggregate market value of $662,143.37 by an individual through Morgan Stanley Smith Barney LLC, acquired via a stock option exercise on May 22, 2026. This notice confirms that the person selling the securities does not know of any material adverse information about the issuer that has not been publicly disclosed.
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet Holdings, Inc. announced that its Board of Directors has approved a quarterly cash dividend of $0.24 per share for the second quarter of 2026. This dividend is payable on or about July 31, 2026, to stockholders of record as of the close of business on June 25, 2026. The company is a global medical technology leader focusing on improving health through innovative products and integrated digital and robotic technologies.
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet Holdings, Inc. announced that its Board of Directors has approved a quarterly cash dividend of $0.24 per share for the second quarter of 2026. This dividend is payable on or about July 31, 2026, to stockholders of record as of June 25, 2026. The company is a global medical technology leader focused on maximizing mobility and improving health through innovative products.
Lantheus weighs potential $7 billion sale following offer from Curium - Bloomberg news
Lantheus Holdings Inc. is reportedly considering a potential sale for approximately $7 billion after receiving an offer from Curium. This news, originally reported by Bloomberg, suggests a significant development for the radiopharmaceutical company. Lantheus (LNTH) is exploring its options following the acquisition proposal.
Thermo Fisher (TMO) director gets 499-share award, 80 withheld for tax
Thermo Fisher Scientific director Dion J. Weisler received a grant of 499 shares of common stock. Concurrently, 80.287 shares were withheld at a price of $451.79 per share to cover tax obligations related to this award. Following these transactions, Weisler's direct holdings in Thermo Fisher amount to 4,947.384 shares.
92% turnout backs Waters (NYSE: WAT) board, auditor and pay
Waters Corporation announced the results of its annual shareholder meeting, revealing that approximately 92.4% of eligible shares were represented. Shareholders re-elected all nominated directors, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and approved a non-binding advisory resolution for executive compensation. The strong turnout and approval rates indicate substantial shareholder support for the company's governance, audit functions, and pay practices.
Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement
Gilead Sciences Inc. (GILD) stock closed up by 3.04% on May 22, outperforming its sector, driven primarily by significant advancements in its product pipeline and regulatory milestones. Key drivers include the FDA approval of Hepcludex for chronic hepatitis delta virus infection and the European Medicines Agency's positive recommendation for Trodelvy in advanced breast cancer. Despite some reports of insider selling and a lowered Q4 2026 EPS estimate, these positive developments provided a strong catalyst for the stock's upward movement.
Lantheus Holdings stock hits 52-week high at 101.01 USD
Lantheus Holdings Inc. stock reached a new 52-week high of $101.01, demonstrating strong performance with a 27.74% appreciation over the past year and a 69% surge in the last six months. This milestone is supported by positive analyst revisions and a "GREAT" financial health rating from InvestingPro, as well as impressive Q1 2026 financial results that surpassed analyst expectations in both adjusted earnings per share and revenue.
Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium
Lantheus Holdings Inc. is reportedly considering a sale after receiving a takeover offer from Curium, valuing the radiopharma company at approximately $7 billion. Discussions between the two companies are ongoing, and a deal could be finalized within weeks, though there is no guarantee of an agreement.
Align Technology Expands Global Operations With Plans for New Multi-Million Dollar Manufacturing Facility in Hyderabad, India
Align Technology (Nasdaq: ALGN) announced plans to open a new manufacturing facility in Hyderabad, India, in 2027. This facility, representing an approximate $200 million investment, will create over 300 jobs and is intended to strengthen Align's supply chain, enhance operational efficiency, and support high-growth markets like India. The move further solidifies Hyderabad's role in Align's global operations, complementing existing facilities like its Global Capability Center and Innovation Center.
Kura Oncology (KURA) CCO sells 10,000 shares in planned trade
Kura Oncology's Chief Commercial Officer, Brian T. Powl, sold 10,000 shares of common stock at $11.00 per share in an open-market transaction. This sale, totaling $110,000, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the transaction, Powl directly holds 173,614 shares of Kura Oncology.
Thermo Fisher (NYSE: TMO) director receives 499-share stock award
Thermo Fisher Scientific director Jennifer M. Johnson was granted 499 shares of common stock, recorded at $0.00 per share, as part of her director compensation. This transaction, filed on Form 4, increased her direct holdings to 1,403 shares. The grant highlights stock-based compensation for directors, rather than an open-market purchase.
Haemonetics (HAE) Upgraded to Buy by Bank of America, Target Price Raised to $80
Bank of America upgraded Haemonetics (HAE) from Neutral to Buy, increasing its target price to $80, citing conservative guidance and potential for outperformance in its vascular closure and plasma segments. GuruFocus assesses HAE as currently undervalued by 22.7% with a strong GF Score of 80/100, driven by solid profitability and growth, despite low momentum. This suggests potential for future gains, although no recent insider activity has been reported.
Big 2025 loss and new capital authorizations at Inventiva (IVA)
Inventiva (IVA) has announced its Annual General Meeting (AGM) for June 30, 2026, where shareholders will vote on resolutions including the approval of a significant net accounting loss of EUR 207.97 million for 2025. This loss has pushed shareholders' equity below half of the share capital, necessitating a commitment to restore equity to avoid dissolution. The company is also seeking broad authorizations for future capital increases, including share buybacks and various types of share and debt security issuances up to a nominal cap of EUR 2 million for shares and EUR 500 million for debt securities, alongside executive and employee equity plans.
Director at Thermo Fisher (NYSE: TMO) awarded 499 common shares
Thermo Fisher Scientific director Harris C. Martin was awarded 499 shares of common stock on May 20, 2026, at no cash cost, which is a compensation-related grant. This transaction increased his direct holdings to 9,532 shares. The Form 4 filing indicates this was a grant, not an open-market purchase or sale.
[Form 4] Immunovant, Inc. Insider Trading Activity
Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, reported selling 3,115 shares of common stock on May 20, 2026, at prices ranging from $30.41 to $32.95 per share. These sales were not discretionary and were executed solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Melanie directly holds 244,973 shares of Immunovant common stock.
Edwards Lifesciences (EW) Form 144: Broker-listed proposed sale notice
Edwards Lifesciences Corporation (EW) has filed a Form 144 notice disclosing a proposed sale of securities through Charles Schwab & Co., Inc. The filing indicates a Performance Stock Lapse of 1,359 shares dated May 7, 2023, and a Restricted Stock Lapse of 141 shares dated May 8, 2023. This is an administrative disclosure for proposed sales and does not confirm actual transactions.
[Form 4] ICU MEDICAL INC/DE Insider Trading Activity
ICU Medical Inc.'s President, Daniel Woolson, reported an open-market sale of 2,123 shares of common stock at a weighted average price of $132.2114 per share, totaling approximately $280,685. Following this transaction, Woolson directly holds 22,479 shares. The Form 4 filing indicates the sale occurred on May 22, 2026, with trade prices ranging from $132.03 to $132.33.
69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR)
Immunocore Holdings Plc has filed to sell 69,271 ADRs through a same-day cashless exercise and sale scheduled for May 26, 2026, with cash settlement brokered by J.P. Morgan Securities LLC. The filing also details recent sales by David Berman, including 11,832 ADRs sold on March 11, 2026, 25,000 on April 8, 2026, and 65,000 on May 21, 2026. The transaction is reported as having a neutral filing impact and sentiment, outlining key figures and definitions related to the Form 144 filing process.
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announce that investors who lost money with Gossamer Bio, Inc. (NASDAQ: GOSS) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Gossamer Bio made misleading statements regarding its Phase 3 PROSERA study, which failed to meet its primary endpoint due to unexpected patient performance on the placebo in Latin American sites. Investors who suffered losses between June 16, 2025, and February 20, 2026, are encouraged to contact the law firm before the lead plaintiff deadline of June 1, 2026.
Nuvation Bio (NUVB) Collaborates with Thermo Fisher
Nuvation Bio Inc. (NYSE:NUVB) completed the technology transfer and product introduction of IBTROZI-taletrectinib to Thermo Fisher Scientific for the treatment of ROS1-positive non-small cell lung cancer. The company recently reported Q1 EPS of 1c on revenue of $83.23M, surpassing consensus estimates. Nuvation Bio is also advancing safusidenib for IDH1-mutant glioma and expects to provide updates on its drug-drug conjugate platform later this year.
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
Lowey Dannenberg P.C. is investigating ImmunityBio Inc. (NASDAQ: IBRX) for potential violations of federal securities laws. A complaint alleges that the company and an officer misrepresented Anktiva’s capabilities, leading to false and misleading statements about ImmunityBio's business. The firm encourages investors who suffered losses exceeding $50,000 to contact them regarding potential participation in the investigation.
LFMDP | LifeMD, Inc. 8.875% Series Insider Trading
This article provides a detailed overview of insider trading, institutional ownership, and other financial data for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred (LFMDP). It highlights the absence of recent congressional trading data, whale activity, and insider trading by company management. The page also offers various tools and metrics for analyzing the stock, including historical performance data and an "About" section describing LifeMD's patient-centric telehealth services.
Kura Oncology’s SWOT analysis: biotech stock faces launch test
Kura Oncology (NASDAQ:KURA) is at a critical stage following the regulatory approval and initial commercial launch of its leukemia treatment, Komzifti. Despite lower-than-expected initial sales, analysts remain confident in the drug's long-term potential, especially with ongoing clinical trials expanding into larger market opportunities for first-line AML treatment. The company's financial health, characterized by more cash than debt, supports its transition from a clinical-stage to a commercial biotech, but continued losses are projected as it invests in launch infrastructure and further clinical development.
Pitt spinout gives surgeons Apple Vision Pros to solve workflow delays
A University of Pittsburgh startup is commercializing research that equips surgeons with Apple Vision Pros to improve workflow efficiency. The technology has been tested in eight surgery trials and is supported by Apple. This initiative aims to integrate advanced augmented reality into surgical procedures.
CNC Maintained by UBS -- Price Target Raised to $61.00
UBS analyst A.J. Rice has maintained a Neutral rating on Centene (CNC) and raised its price target from $55.00 to $61.00, indicating a positive outlook for the stock. GuruFocus calculates Centene's GF Value™ at $84.03, suggesting the stock is undervalued by 30.3%. The company holds a GF Score™ of 67/100, reflecting strong profitability and financial stability despite challenges in rapid revenue growth.
West Pharmaceutical Services Gains Spotlight In S&P 500 Momentum
West Pharmaceutical Services (WST) is attracting attention within the S&P 500 due to its role in healthcare packaging and injectable delivery solutions. The article highlights the increasing demand for specialized pharmaceutical delivery systems driven by pharmaceutical innovation, particularly in injectable therapies and biologic medicines. The company's focus on advanced drug manufacturing and specialized healthcare supply chain operations positions it well within the current market trends.
Lineage reports positive 36-month findings on GA cell therapy
Lineage Cell Therapeutics announced positive 36-month results from a phase 1/2a clinical trial for RG6501 (OpRegen), a cell therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The findings showed sustained gains in best-corrected visual acuity and retinal structural improvements, particularly in patients with less advanced GA and extensive OpRegen coverage. These results suggest the therapy provides durable support to retinal cells, challenging the view that GA is an irreversible condition.
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead Sciences has received accelerated FDA approval for Hepcludex® (bulevirtide-gmod) as the first and only approved treatment for adults with chronic hepatitis delta virus (HDV) infection in the United States. Chronic HDV is the most severe form of viral hepatitis, leading to rapid liver disease progression, and the approval addresses a significant unmet medical need. The approval is based on data from the Phase 3 MYR301 study showing significant reductions in HDV RNA and normalization of ALT, with continued approval contingent on confirmatory trials.
US FDA approves Gilead's drug for deadly liver infection
The U.S. FDA has approved Gilead Sciences' drug Hepcludex for treating chronic hepatitis delta virus (HDV), a rare and deadly liver infection. This approval addresses a critical unmet medical need, as there were previously no FDA-approved treatments for HDV, which can lead to severe liver damage and death. The drug is significant for patients already infected with hepatitis B, who are susceptible to HDV.
US FDA approves Gilead's drug for deadly liver infection
The U.S. Food and Drug Administration has approved Gilead Sciences' drug, Hepcludex, for the treatment of chronic hepatitis delta virus (HDV). This rare and deadly liver infection previously had no approved treatment options, leading to conditions like scarring, cancer, organ failure, and death. The approval addresses a critical gap in care for affected patients.
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead Sciences has received accelerated FDA approval for Hepcludex (bulevirtide-gmod), making it the first and only approved treatment for chronic hepatitis delta virus (HDV) in the United States. This approval addresses a significant unmet medical need for HDV, considered the most severe form of viral hepatitis, based on data showing reductions in HDV RNA and normalization of alanine aminotransferase (ALT) in the Phase 3 MYR301 study. Continued approval for this indication will be contingent upon verification of clinical benefit in a confirmatory trial.
Henry Schein Elects William K. “Dan” Daniel as Independent Chairman of the Board, Succeeding Stan Bergman After 44 Years
Henry Schein, Inc. has announced the election of William K. “Dan” Daniel as the new Independent Chairman of the Board, effective May 21, 2026. This appointment follows the retirement of long-serving Chairman Stanley M. Bergman, who has been named Chairman Emeritus after 44 years with the company. The transition occurs as Henry Schein continues to implement its strategy to become a leading integrated solutions platform in healthcare, with Daniel bringing extensive executive experience from Danaher Corporation to his new role.
Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder
This article lists several companies, including AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova, and Estee Lauder, under the heading "Final trades". Without additional content, the specific context or recommendation for these trades cannot be determined.
IOVA Stock Slides As Guidance Tops Wall Street Expectations
Iovance Biotherapeutics (IOVA) stock experienced an 11% slide despite issuing Q2 and full-year 2026 revenue guidance that exceeded or met Wall Street expectations, driven by strong Amtagvi adoption. The company reported $71M in Q1 2026 revenue, falling short of analyst estimates, but highlighted a cash runway into 2028. Analysts have trimmed price targets but maintained a "Buy" rating, indicating tempered yet constructive outlook for the company's leading T-cell therapy.
DBV Technologies Stock Rebounds 2% After Prolonged Decline
DBV Technologies stock rebounded by 2% in mid-session trading, despite remaining below its short-term moving averages and down over the past week and three months. The company is poised for significant regulatory milestones in 2026, with planned FDA Biologics License Application submissions for its Viaskin Peanut allergen patch. Despite a slight increase in short positions, the underlying context reflects a biotech firm with substantial regulatory stakes and a comfortable cash reserve until Q2 2027.
Gilead Sciences stock rises after FDA approves HDV treatment
Gilead Sciences Inc. (NASDAQ:GILD) shares rose 2.5% after the FDA approved Hepcludex (bulevirtide-gmod) for treating chronic hepatitis delta virus (HDV) infection in adults. This marks the first FDA-approved treatment for HDV, a serious condition that can lead to severe liver disease. Clinical trials demonstrated Hepcludex's efficacy, with a significant combined response and undetectable HDV RNA rates.
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial
Edesa Biotech (NASDAQ:EDSA) is preparing to initiate a Phase 2 clinical trial for EB06, its anti-CXCL10 monoclonal antibody, in patients with moderate-to-severe non-segmental vitiligo in mid-2026. The company is also advancing regulatory discussions for its ARDS treatment, paridiprubart (EB05), following positive Phase 3 results showing a significant mortality benefit. Edesa reported no revenue for Q2 FY2026, with R&D expenses increasing due to manufacturing preparations for the EB06 trial, and had $10.0 million in cash as of March 31, 2026.
Final Trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder
The article highlights the "Halftime Report" Investment Committee's top stock picks for the remainder of the trading day. The featured companies are AbbVie, Millrose Properties, Archer-Daniels-Midland (ADM), GE Vernova, and Estee Lauder. The segment suggests these stocks are noteworthy for investors.
Glaukos Plunges 11.2% After BTIG Maintains Buy
Glaukos Corporation shares dropped 11.2% despite BTIG maintaining a "Buy" rating and raising its price target from $141 to $162. This disconnect suggests investor concerns outweigh analyst optimism, possibly due to skepticism about underlying assumptions or unaddressed near-term headwinds in the medical devices sector. Investors are urged to monitor management's commentary on sales trends or competitive dynamics to understand the market's reaction.
These stocks are moving in today's pre-market session
This article details the top gainers and losers in the pre-market session for Friday, June 18, 2021, providing stock tickers, percentage changes, and brief explanations for significant movements, often citing recent press releases or company news. Leading gainers include CAI with a 46.15% rise due to an acquisition agreement and SYKE up 29.85% following a new agreement. Conversely, ORPH plummeted 52.68% and ATHA dropped 38.6% due to negative news or ongoing declines.
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks
This article identifies MindWalk Holdings, Myriad Genetics, and Douglas Elliman as promising penny stocks, highlighting their financial health and growth potential. MindWalk Holdings, a bio-native AI company, has significantly reduced its net loss and has no debt. Myriad Genetics, a molecular diagnostics firm, shows sales growth despite unprofitability and increased debt. Douglas Elliman, a real estate services company, operates without debt but reported a net loss in Q1 2026, though strategic moves could bolster future performance.
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis
Agilent Technologies has launched the Agilent 9500 Triple Quadrupole ICP-MS, a new inductively coupled plasma mass spectrometry system designed to simplify the transition for laboratories from single to triple quadrupole technology for advanced trace elemental analysis. This system aims to improve productivity, streamline interference removal, and provide high-quality data more easily, addressing challenges faced by labs with increasing testing demands and limited skilled resources. The 9500 ICP-MS offers faster data acquisition, reduced costs, and enhanced interference removal, making advanced analysis more accessible for various applications including environmental, food, and pharmaceutical testing.
UnitedHealth set to snap six straight sessions of losses (UNH:NYSE)
UnitedHealth Group (UNH) shares are poised to end a six-session losing streak, rising 1.6% to $388.9 in afternoon trading. The health insurer had previously lost over 4% across the preceding six sessions, despite having risen nearly 17% year-to-date. Key drivers for UNH include strong revenue growth, positive analyst ratings, and proactive capital management, though risks such as government intervention and antitrust investigations remain.
Haemonetics Corporation Stock 12‑Month Price Target Raised to $81, Implies 31% Upside
Analysts have raised the 12-month price target for Haemonetics Corporation (HAE) stock to $81, up from $80.2, with a range spanning $62 to $104 per share. This new target suggests a 31% potential upside based on the closing price of May 21. The consensus rating among 11 analysts remains a "Buy," with 8 Buy ratings and 3 Holds.
BofA analysts downgrade Inspire Medical on reimbursement coding concerns
BofA has downgraded Inspire Medical (NYSE:INSP) from "Neutral" to "Underperform" due to significant concerns regarding reimbursement coding for its Inspire V neuromodulation procedure. The company's prior guidance cut for 2026 and the continued lack of clarity on appropriate CPT coding, along with increasing competition and other market factors, led to the downgrade. Analysts do not foresee a sustainable improvement in the stock until a clear coding pathway is established, which is not expected until at least 2028.
Reasons to Retain STE Stock in Your Portfolio for Now
STERIS plc (STE) is recommended for retention due to its strong Healthcare and Applied Sterilization Technologies (AST) segments, which show robust market adoption and service revenue growth, respectively. Despite macroeconomic volatilities and foreign exchange risks, the company's positive financial outlook, including an earnings yield above its industry average, suggests it can navigate these challenges. Analysts project a 0.4% increase in EPS for fiscal 2027 and a 7.4% growth in revenues, indicating continued financial health.
Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?
Medtronic (MDT) announced its intent to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) therapies for chronic pain management. This acquisition is expected to expand Medtronic's pain therapy portfolio, which already includes spinal cord stimulation and nerve ablation, to meet the growing demand for non-opioid pain relief. The deal, valued at approximately $650 million, aims to strengthen Medtronic's neuromodulation capabilities and support more patients with minimally invasive options.
